Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip
Advanced Healthcare Materials · 2023
DOI: 10.1002/adhm.202300591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Haijun Cui und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biological and Chemical Systems - Functional Molecular Systems (IBCS-FMS), Karlsruhe Institute of Technology (KIT), Hermann-von-Helmholt…. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Deutsche Krebshilfe, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
To address the challenge of drug resistance and limited treatment options for recurrent gliomas with IDH1 mutations, a highly miniaturized screening of 2208 FDA‐approved drugs is conducted using a high‐throughput droplet microarray (DMA) platform. Two patient‐derived temozolomide‐resistant tumorspheres harboring endogenous IDH1 mutations (IDH1 mut ) are utilized. Screening identifies over 20 drugs, including verteporfin (VP), that significantly affected tumorsphere formation and viability. Proteomics analysis reveals that nuclear pore complex may be a potential VP target, suggesting a new mechanism of action independent of its known effects on YAP1. Knockdown experiments exclude YAP1 as a drug target in tumorspheres. Pathway analysis shows that NUP107 is a potential upstream regulator associated with VP response. Analysis of publicly available genomic datasets shows a significant correlation between high NUP107 expression and decreased survival in IDH1 mut astrocytoma, suggesting NUP107 may be a potential biomarker for VP response. This study demonstrates a miniaturized approach for cost‐effective drug repurposing using 3D glioma models and identifies nuclear pore complex as a potential target for drug development. The findings provide preclinical evidence to support in vivo and clinical studies of VP and other identified compounds to treat IDH1 mut gliomas, which may ultimately improve clinical outcomes for patients with this challenging disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biological and Chemical Systems - Functional Molecular Systems (IBCS-FMS), Karlsruhe Institute of Technology (KIT), Hermann-von-Helmholtz-Platz 1, 76344, Eggenstein-Leopoldshafen, Germany.
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400044, China.
- Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
- Institute for Automation and Applied Informatics (IAI), Karlsruhe Institute of Technology (KIT), Hermann-von-Helmholtz-Platz 1, 76344, Eggenstein-Leopoldshafen, Germany.
- Institute of Organic Chemistry (IOC), Karlsruhe Institute of Technology (KIT), Fritz-Haber Weg 6, 76131, Karlsruhe, Germany.
ORCID-Profile: Şevin Turcan
Förderung
- National Natural Science Foundation of China
- Deutsche Krebshilfe
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Cui, H., Sun, X., Schilling, M., Herold-Mende, C., Reischl, M., Levkin, P. A., Popova, A. A., & Turcan, Ş. (2023). Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202300591
Vancouver
Cui H, Sun X, Schilling M, Herold-Mende C, Reischl M, Levkin PA, et al. Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202300591
BibTeX
@article{Cui2023,
author = {Cui, Haijun and Sun, Xueyuan and Schilling, Marcel and Herold-Mende, Christel and Reischl, Markus and Levkin, Pavel A and Popova, Anna A and Turcan, Şevin},
title = {Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip},
journal = {Advanced Healthcare Materials},
year = {2023},
doi = {10.1002/adhm.202300591}
}
EUVIMED